JANXJanux Therapeutics, Inc.
$18.51-18% 1Y
$18.51
$12.1852 weeks$34.74
JANX in its own filings
JANX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
98
Events found in the filings · across 440 filings · the record starts in 2021
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- May 14, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Delisting notice / listing-rule failurehistorical
- 2023-06-20
- SEC comment-letter activity8 occurrences
- 2022-09-15
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Jun 23, 2026On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as …Other event · Form 8-K
- May 7, 2026Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Apr 28, 2026In order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), the Board determined that one of its members should be reclassified from Class III (with a term expiring at the Company’s 2027 Annual Meeting …Director or officer change · Form 8-K
- Feb 26, 2026Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights.Earnings release · press release
- Jan 22, 2026On January 21, 2026, Janux Therapeutics, Inc. (“Janux” or the “Company”) and Bristol-Myers Squibb Company (“BMS”) entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid …Material agreement entered · Form 8-K
- Nov 6, 2025Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights.Earnings release · press release
- Sep 19, 2025Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc. (the “Company”), ceased to serve as Chief Strategy Officer of the Company and departed from the Company effective September 18, 2025 under circumstances that the Company determined to constitute a termination without “Cause” under …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…